75833-38-4

Basic information

• Product Name: 2-Chloropyrimidine-4-carbonitrile
• Synonyms: 4-Pyrimidinecarbonitrile, 2-chloro- (7CI,9CI);2-Chloro-4-pyrimidinecarbonitrile;2-Amino-4-cyanopyrimidine;2-Chloro-4-cyanopyrimidine;2-chloro-4-cyanopyrmidine;2-ChloropyriMidine-4-carb...;4-PyriMidinecarbonitrile,2-chloro-;2-Chloro-4-cyanopyrimidine, 2-Chloro-4-cyano-1,3-diazine
• CAS NO: 75833-38-4
• Molecular Formula: C₅H₂ClN₃
• Molecular Weight: 139.54248
• Product Categories: PYRIMIDINE;pharmacetical;Building Blocks;Heterocycle-Pyrimidine series
• Mol File: 75833-38-4.mol

Chemical Properties

• Melting Point: 53-55°
• Boiling Point: 331.279 °C at 760 mmHg
• Flash Point: 154.152 °C
• Appearance: /
• Density: 1.43
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.96±0.20(Predicted)
• CAS DataBase Reference: 2-Chloropyrimidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloropyrimidine-4-carbonitrile(75833-38-4)
• EPA Substance Registry System: 2-Chloropyrimidine-4-carbonitrile(75833-38-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• RIDADR: 3439
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 75833-38-4(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 1, p. 130, 1964 DOI: 10.1002/jhet.5570010305

InChI:InChI=1/C5H4N4/c6-3-4-1-2-8-5(7)9-4/h1-2H,(H2,7,8,9)

Upstream product

• 7460-56-2 2-oxo-1,2-dihydro-pyrimidine-4-carbaldehyde oxime 
• 950514-12-2 2-hydroxy-4-pyrimidinecarboxaldehyde 
• 7460-56-2 2-hydroxy-pyrimidine-4-carbaldehyde oxime 
• 557-21-1 zinc(II) cyanide 
• 3934-20-1 2,6-Dichloropyrimidine 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 75825-52-4 2-(2-Methoxy-phenylamino)-pyrimidine-4-carbonitrile 
• 75825-51-3 2-(4-chlorophenylamino)pyrimidine-4-carbonitrile 
• 75825-53-5 2-(4-Dimethylamino-phenylamino)-pyrimidine-4-carbonitrile 
• 75825-59-1 2-methoxypyrimidine-4-carboxylic acid methyl ester 
• 79605-00-8 2-dimethylaminopyrimidine-4-carbonitrile 
• 75825-49-9 2-Diethylamino-pyrimidine-4-carbonitrile 
• 955112-52-4 tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate 
• 75825-60-4 2-methoxypyrimidine-4-carboxylic acid 
• 75825-56-8 2-(4-Chloro-phenylamino)-pyrimidine-4-carboxylic acid 
• 75825-57-9 2-(2-methoxy-phenylamino)-pyrimidine-4-carboxylic acid 
• 79605-02-0 2-dimethylaminopyrimidine-4-carboxamidinium benzenesulfonate 
• 75928-84-6 2,4-Dicyanpyrimidin 
• 1124-75-0 2-Methylmercapto-4-cyan-pyrimidin 
• 22536-66-9 2-chloro-4-pyrimidinecarboxamide 

Relevant articles and documents

Synthesis method of 2-chloropyrimidine-4-formic acid

The invention relates to a synthesis method of 2-chloropyrimidine-4-formic acid. 2, 4-dichloropyrimidine is used as a starting raw material, the target product 2-chloropyrimidine-4-formic acid is prepared through a two-step reaction, and the whole synthesis process is high in yield, the purity is good, and the operation is convenient, green and environmentally friendly, therefore the method is suitable for industrial production.

Synthesis method of 2-chlorine-4-cyano pyridine

The invention discloses a synthesis method of 2-chlorine-4-cyano pyridine. The synthesis method includes the following steps that first, the 2-hydroxide radical-4-methylpyrimidine and diluted hydrochloric acid are mixed in a reactor according to the weight ratio of 1:(1 to 5), and cooled, and a sodium nitrite aqueous solution is dropwise added at 0-5 DEG C, after dropwise adding, the insulation reaction is kept at 0-5 DEG C for 2-3 hours, filtering and drying are conducted to obtain an intermediate for standby application, and second, the intermediate in the first step, phosphorus oxychlorideand organic alkali are mixed according to the weight ratio of 1:(5 to 10):(0.3 to 0.7) and the chlorination reaction is conducted at 25-100 DEG C for 2-5 hours, after the mixture is cooled, excess phosphorus oxychloride is removed under reduced pressure and concentration, and after quenching with water, extraction with the organic solvent, drying, and recrystallization after concentration are conducted to obtain the product 2-chlorine-4-cyano pyridine. According to the synthesis method of the 2-chlorine-4-cyano pyridine, the synthesis route is short, synthesis is convenient, yield is high, thetoxicity of raw materials is small, and the purity of the purified product is high.

NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK

The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases s

DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS

The present invention is concerned with diazaspiroalkanone- substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human a

COMPOSITIONS AND METHODS FOR TREATING CANCER

The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is MK-1775 or a pharmaceutically acceptable salt thereof, or MK-3652 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is MK-8776 or a pharmaceutically acceptable salt thereof, or SCH900444 or a pharmaceutically acceptable salt thereof.

AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

AMINOPYRIMIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

A compound of formula 1 efficiently inhibit several protein kinases including glycogen synthase kinase 3 (GSK), aurora kinase, extracellular signal- regulated kinase (ERK), protein kinase B (AKT), and the likes, to control signal transductions involved in

Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof

This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A1, A2, A3, R1-R4, X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.